Salud financiera de hoja de balance de Agios Pharmaceuticals
Salud financiera controles de criterios 6/6
Agios Pharmaceuticals tiene un patrimonio de los accionistas total de $1.6B y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $1.8B y $165.1M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$1.00b |
| Patrimonio | US$1.63b |
| Total pasivo | US$165.12m |
| Activos totales | US$1.79b |
Actualizaciones recientes sobre salud financiera
We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate
Sep 26
Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth
Jun 02Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Jan 16Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Sep 26We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely
Feb 06Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans
Oct 18Recent updates
We're Not Very Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Rate
Sep 26Agios' Mitapivat: A Potential Blockbuster In Thalassemia Treatment
Aug 27Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Aug 04Agios Pharmaceuticals: Potential Acquisition Target, Upcoming FDA Approvals, Promising Pipeline
Jun 12Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth
Jun 02Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates
Feb 17Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Jan 16Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 50%
Nov 09Here's Why We're Not Too Worried About Agios Pharmaceuticals' (NASDAQ:AGIO) Cash Burn Situation
Sep 26Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?
May 08We're Hopeful That Agios Pharmaceuticals (NASDAQ:AGIO) Will Use Its Cash Wisely
Feb 06Agios Pharmaceuticals (NASDAQ:AGIO) Is In A Good Position To Deliver On Growth Plans
Oct 18Agios Pyrukynd for rare blood disorder gets EMA panel backing for approval in EU
Sep 16Agios adds more than 13% after Novo deal to acquire rival Forma
Sep 01Agios Pharmaceuticals GAAP EPS of -$1.68 beats by $0.07
Aug 04Agios Pharmaceuticals Is A Buy On Coming Revenue Ramp
Jul 26Agios Pharmaceuticals appoints new board chair, CEO
Jul 12Agios: Approved Product, Upcoming Catalysts
May 10Are Investors Undervaluing Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) By 48%?
May 10Agios Pharmaceuticals With FDA Approval Is A Buy
Feb 23Agios Before The February PDUFA
Jan 20Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Analysts Just Trimmed Their Revenue Forecasts By 46%
Dec 21Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($1.1B) de AGIO superan a sus pasivos a corto plazo ($119.5M).
Pasivo a largo plazo: Los activos a corto plazo de AGIO ($1.1B) superan a sus pasivos a largo plazo ($45.7M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: AGIO está libre de deudas.
Reducción de la deuda: AGIO no tenía deudas hace 5 años.
Cobertura de la deuda: AGIO no tiene deuda, por lo tanto no necesita estar cubierta por flujo de caja operativo.
Cobertura de intereses: AGIO no tiene deuda, por lo que la cobertura de pagos de intereses no es motivo de preocupación.